Mabion
Mabion S.A., a biotechnology company, researches and develops biotechnology and biosimilar drugs to treat cancer, autoimmune, and metabolic diseases in Poland. The last earnings update was 40 days ago. More info.
Add to Portfolio Compare Print
MAB Share Price and Events
7 Day Returns
1 Year Returns
MAB Shareholder Return
| 7 Day | 30 Day | 90 Day | 1 Year | 3 Year | 5 Year | |
|---|---|---|---|---|---|---|
| Mabion (MAB) | 2.8% | -13.5% | 3.7% | -20% | -5.5% | 41.9% |
| PL Biotechs | 0.9% | -9.6% | -0.1% | -24.3% | -31.3% | 5.5% |
| PL Market | -0.9% | -7.1% | -6.3% | -7.4% | 9.6% | -11.5% |
1 Year Return vs Industry and Market
- MAB outperformed the Biotechs industry which returned -24.3% over the past year.
- MAB underperformed the Market in Poland which returned -7.4% over the past year.
MAB Value
Is Mabion undervalued based on future cash flows and its price relative to the stock market?
Value is all about what a company is worth versus what price it is
available for. If you went into a grocery store and all the bananas were on sale
at half price, they could be considered
undervalued.
- It is not possible to calculate the future cash flow value for Mabion. This is due to cash flow or dividend data being unavailable. The share price is PLN73.1.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.The amount the stock market is willing to pay for Mabion's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are
Mabion's earnings available for a low price, and how does
this compare to other companies in the same industry?
| Data Point | Source | Value |
|---|---|---|
| Earnings Per Share * | Company Filings (2018-12-31) in PLN | PLN-5.26 |
| WSE:MAB Share Price ** | WSE (2019-05-20) in PLN | PLN73.1 |
| Europe Biotechs Industry PE Ratio | Median Figure of 29 Publicly-Listed Biotechs Companies | 22.03x |
| Poland Market PE Ratio | Median Figure of 463 Publicly-Listed Companies | 10.7x |
* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.
** Primary Listing of Mabion.
| Calculation | Outcome | |
|---|---|---|
| PE Ratio | = WSE:MAB Share Price ÷ EPS (both in PLN) = 73.1 ÷ -5.26 |
-13.89x |
Learn more about our ratios and growth rates in Simply Wall St’s analysis model >
- Mabion is loss making, we can't compare its value to the Europe Biotechs industry average.
- Mabion is loss making, we can't compare the value of its earnings to the Poland market.
Price based on expected Growth
Does
Mabion's expected growth come at a high price?
| Data Point | Source | Value |
|---|---|---|
| PE Ratio | See PE Ratio Section | -13.89x |
| Net Income Annual Growth Rate | See Future Growth Section. Line of Best Fit* through Consensus Estimate Earnings of 1 Analysts |
Not available |
| Europe Biotechs Industry PEG Ratio | Median Figure of 23 Publicly-Listed Biotechs Companies | 1.29x |
| Poland Market PEG Ratio | Median Figure of 113 Publicly-Listed Companies | 0.93x |
*Line of best fit is calculated by linear regression .
Learn more about our ratios and growth rates in Simply Wall St’s analysis model >
- Unable to calculate PEG ratio for Mabion, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on
Mabion's
assets?
| Data Point | Source | Value |
|---|---|---|
| Book Value per Share | Company Filings (2018-12-31) in PLN | PLN3.07 |
| WSE:MAB Share Price * | WSE (2019-05-20) in PLN | PLN73.1 |
| Poland Biotechs Industry PB Ratio | Median Figure of 8 Publicly-Listed Biotechs Companies | 1.84x |
| Poland Market PB Ratio | Median Figure of 689 Publicly-Listed Companies | 0.97x |
| Calculation | Outcome | |
|---|---|---|
| PB Ratio | = WSE:MAB Share Price ÷ Book Value per Share (both in PLN) = 73.1 ÷ 3.07 |
23.8x |
* Primary Listing of Mabion.
Learn more about our ratios and growth rates in Simply Wall St’s analysis model >
- Mabion is overvalued based on assets compared to the PL Biotechs industry average.
Value checks
We assess Mabion's value by looking at:- Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
- Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
- Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
- Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check) Mabion has a total score of 0/6, see the detailed checks below.
Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.
Full details on the Value part of the Simply Wall St company analysis model.
MAB Future Performance
How is Mabion expected to perform in the next 1 to 3 years based on estimates from 1 analyst?
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Mabion has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.
Show me the analysis anyway
The future performance of a company is measured in the same way as past
performance, by looking at estimated
growth
and how much profit it is expected to make.Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Earnings growth vs Low Risk Savings
- Unable to compare Mabion's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
- Unable to compare Mabion's earnings growth to the Poland market average as no estimate data is available.
- Unable to compare Mabion's revenue growth to the Poland market average as no estimate data is available.
Annual Growth Rates Comparison
| Data Point | Source | Value (per year) |
|---|---|---|
| Europe Biotechs Industry Earnings Growth Rate | Market Cap Weighted Average | 20% |
| Europe Biotechs Industry Revenue Growth Rate | Market Cap Weighted Average | 14.3% |
| Poland Market Earnings Growth Rate | Market Cap Weighted Average | 10% |
| Poland Market Revenue Growth Rate | Market Cap Weighted Average | 5.5% |
*Line of best fit is calculated by linear regression .
Industry and Market average data is calculated daily.
Learn more about our growth rate calculations in Simply Wall St’s analysis model.
Analysts growth expectations
| Data Point | Source | Value |
|---|---|---|
| Past Financials | Company Filings (4 months ago) | See Below |
| Future Estimates | Average of up to 1 Analyst Estimates (S&P Global) | See Below |
| Date (Data in PLN Millions) | Revenue | Cash Flow | Net Income * | Avg. No. Analysts |
|---|---|---|---|---|
| 2020-12-31 | 140 | 1 | ||
| 2019-12-31 | 0 | 1 |
| Date (Data in PLN Millions) | Revenue | Cash Flow | Net Income * |
|---|---|---|---|
| 2018-12-31 | -39 | -69 | |
| 2018-09-30 | -42 | -72 | |
| 2018-06-30 | -62 | -74 | |
| 2018-03-31 | -61 | -59 | |
| 2017-12-31 | -54 | -58 | |
| 2017-09-30 | -35 | -56 | |
| 2017-06-30 | -24 | -57 | |
| 2017-03-31 | -26 | -59 | |
| 2016-12-31 | -15 | -56 | |
| 2016-09-30 | 0 | -36 | -77 |
| 2016-06-30 | 0 | -44 | -65 |
| 2016-03-31 | 3 | -30 | -51 |
*GAAP earnings excluding extraordinary items.
Past and Future Earnings per Share
| Data Point | Source | Value |
|---|---|---|
| Past Financials | Company Filings (4 months ago) | See Below |
| Future Estimates | Average of up to 1 Analyst Estimates (S&P Global) | See Below |
All data from Mabion Company Filings, last reported 4 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.
| Date (Data in PLN Millions) | EPS * | EPS High Estimate | EPS Low Estimate | Avg. No. Analysts |
|---|---|---|---|---|
| 2020-12-31 | ||||
| 2019-12-31 |
| Date (Data in PLN Millions) | EPS * |
|---|---|
| 2018-12-31 | -5.26 |
| 2018-09-30 | -5.41 |
| 2018-06-30 | -6.08 |
| 2018-03-31 | -5.02 |
| 2017-12-31 | -4.91 |
| 2017-09-30 | -4.75 |
| 2017-06-30 | -4.85 |
| 2017-03-31 | -4.99 |
| 2016-12-31 | -4.84 |
| 2016-09-30 | -6.36 |
| 2016-06-30 | -5.75 |
| 2016-03-31 | -4.54 |
*GAAP earnings excluding extraordinary items.
Future performance checks
We assess Mabion's future performance by looking at:- Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
- Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Europe market? (1 check)
- Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Europe market? (1 check)
- Is the annual earnings growth rate expected to be above 20%? (1 check)
- Is the annual revenue growth rate expected to be above 20%? (1 check)
- Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Mabion has a total score of 0/6, see the detailed checks below.
Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.
Full details on the Future part of the Simply Wall St company analysis model.
MAB Past Performance
How has Mabion performed over the past 5 years?
The past performance of a company can be measured by how much
growth
it has experienced and how much profit it makes relative to the funds and assets
it has available.
Past earnings growth
Past Earnings growth analysis
- Mabion does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
- Unable to compare Mabion's 1-year earnings growth to the 5-year average as it is not currently profitable.
- Unable to compare Mabion's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
All data from Mabion Company Filings, last reported 4 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.
| Date (Data in PLN Millions) | Revenue | Net Income * | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 2018-12-31 | -68.87 | 20.39 | 44.93 | |
| 2018-09-30 | -71.57 | 23.43 | 47.54 | |
| 2018-06-30 | -73.70 | 23.37 | 48.59 | |
| 2018-03-31 | -59.39 | 22.44 | 41.30 | |
| 2017-12-31 | -57.89 | 20.80 | 43.26 | |
| 2017-09-30 | -56.03 | 17.60 | 43.36 | |
| 2017-06-30 | -57.24 | 16.02 | 46.77 | |
| 2017-03-31 | -58.57 | 14.55 | 47.29 | |
| 2016-12-31 | -55.83 | 13.39 | 44.22 | |
| 2016-09-30 | 0.01 | -76.61 | 10.69 | 71.39 |
| 2016-06-30 | 0.01 | -64.51 | 9.05 | 58.63 |
| 2016-03-31 | 2.56 | -51.25 | 7.60 | 47.55 |
| 2015-12-31 | 2.73 | -42.54 | 5.18 | 39.78 |
| 2015-09-30 | 2.96 | -5.85 | 3.56 | |
| 2015-06-30 | 2.98 | -4.68 | 2.85 | |
| 2015-03-31 | 0.64 | -5.16 | 1.70 | |
| 2014-12-31 | 0.83 | -4.46 | 1.40 | |
| 2014-09-30 | 0.50 | -4.40 | 4.28 | |
| 2014-06-30 | 0.48 | -4.08 | 4.17 | |
| 2014-03-31 | -0.10 | -4.26 | 4.15 | |
| 2013-12-31 | 0.01 | -3.89 | 4.24 | |
| 2013-09-30 | -10.08 | -3.49 | 2.06 | |
| 2013-06-30 | -8.60 | -2.93 | 1.88 | |
| 2013-03-31 | 0.01 | -2.19 | 1.59 | |
| 2012-12-31 | 0.89 | -2.12 | 1.30 | |
| 2012-09-30 | 5.69 | -1.93 | 9.00 | |
| 2012-06-30 | 8.40 | -1.52 | 9.00 |
*GAAP earnings excluding extraordinary items.
Performance last year
We want to ensure a company is making the most of what it has available. This is
done by comparing the return (profit) to a company's available
funds,
assets
and
capital.
- It is difficult to establish if Mabion has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
- It is difficult to establish if Mabion has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
- It is difficult to establish if Mabion improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
Past performance checks
We assess Mabion's performance over the past 5 years by checking for:- Has earnings increased in past 5 years? (1 check)
- Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
- Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
- Is the Return on Equity (ROE) higher than 20%? (1 check)
- Is the Return on Assets (ROA) above industry average? (1 check)
- Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
Mabion has a total score of 0/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
Full details on the Past part of the Simply Wall St company analysis model.
MAB Health
How is Mabion's financial health and their level of debt?
A company's financial position is much like your own financial position,
it includes everything you own
(assets)
and owe
(liabilities).The boxes below represent the relative size of what makes up Mabion's finances.
The net worth of a company is the difference between its assets and liabilities.
- Mabion is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
- Mabion's cash and other short term assets cover its long term commitments.
Balance sheet
Assets
Liabilities and shares
- High level of physical assets or inventory.
- Debt is covered by short term assets, assets are 12.8x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t
bad,
however if the debt is too high, or the company can’t afford to pay the interest
on its debts this may have impacts in the future.The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.
If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
All data from Mabion Company Filings, last reported 4 months ago.
| Date (Data in PLN Millions) | Total Equity | Total Debt | Cash & Short Term Investments |
|---|---|---|---|
| 2018-12-31 | 42.14 | 5.64 | 58.53 |
| 2018-09-30 | 58.01 | 5.68 | 67.99 |
| 2018-06-30 | 69.11 | 5.87 | 68.10 |
| 2018-03-31 | -68.51 | 258.45 | 173.34 |
| 2017-12-31 | -54.16 | 66.03 | 1.04 |
| 2017-09-30 | -34.87 | 53.78 | 2.36 |
| 2017-06-30 | -21.64 | 54.74 | 25.02 |
| 2017-03-31 | -9.12 | 26.21 | 13.02 |
| 2016-12-31 | 3.73 | 12.72 | 14.83 |
| 2016-09-30 | 135.21 | 0.10 | 0.06 |
| 2016-06-30 | 137.11 | 0.14 | 0.92 |
| 2016-03-31 | 125.52 | 0.16 | 3.71 |
| 2015-12-31 | 45.46 | 0.23 | 6.07 |
| 2015-09-30 | 95.46 | 0.05 | 1.54 |
| 2015-06-30 | 97.80 | 0.06 | 0.05 |
| 2015-03-31 | 98.39 | 0.06 | 1.18 |
| 2014-12-31 | 99.78 | 0.10 | 6.95 |
| 2014-09-30 | 80.40 | 0.00 | 18.71 |
| 2014-06-30 | 81.58 | 0.00 | 17.62 |
| 2014-03-31 | 51.35 | 0.00 | 0.04 |
| 2013-12-31 | 52.06 | 0.00 | 3.61 |
| 2013-09-30 | 53.52 | 0.00 | 10.56 |
| 2013-06-30 | 54.37 | 0.00 | 31.78 |
| 2013-03-31 | 17.91 | 0.00 | 0.37 |
| 2012-12-31 | 18.24 | 0.02 | 4.50 |
| 2012-09-30 | 19.31 | 0.02 | 5.30 |
| 2012-06-30 | 19.60 | 0.02 | 1.30 |
- Mabion's level of debt (13.4%) compared to net worth is satisfactory (less than 40%).
- The level of debt compared to net worth has increased over the past 5 years (0% vs 13.4% today).
CASH RUNWAY ANALYSIS
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
- Mabion has sufficient cash runway for 1.3 years based on current free cash flow.
- Mabion has sufficient cash runway for 1.3 years if free cash flow continues to grow at historical rates of 15% each year.
Financial health checks
We assess Mabion's financial health by checking for:- Are short term assets greater than short term liabilities? (1 check)
- Are short term assets greater than long term liabilities? (1 check)
- Has the debt to equity ratio increased in the past 5 years? (1 check)
- Is the debt to equity ratio over 40%? (1 check)
- Is the debt covered by operating cash flow? (1 check)
- Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check) Mabion has a total score of 5/6, see the detailed checks below.
- Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
- Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
Full details on the Health part of the Simply Wall St company analysis model.
MAB Dividends
What is Mabion's current dividend yield, its reliability and sustainability?
Dividends are regular cash payments to you from the company, similar to a
bank paying you interest on a savings account.
Annual Dividend Income
If you bought
PLN2,000 of
Mabion
shares you are expected to receive
PLN0
in your first year as a dividend.
Dividend Amount
- Unable to evaluate Mabion's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
- Unable to evaluate Mabion's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not
wildly increasing/decreasing each year. This graph shows you the historical rate
to count toward your assessment of the stock.We also check to see if the dividend has increased in the past 10 years.
| Data Point | Source | Value |
|---|---|---|
| Past Annualized Dividend Yield | S&P Global Market Data | See Below |
| Past Dividends per Share | Company Filings/ Annualized Dividend Payments | See Below |
| Future Dividends per Share Estimates | Average of up to 1 Analyst Estimates (S&P Global) | See Below |
| Europe Biotechs Industry Average Dividend Yield | Market Cap Weighted Average of 9 Stocks | 0.8% |
| Poland Market Average Dividend Yield | Market Cap Weighted Average of 200 Stocks | 4.1% |
| Poland Minimum Threshold Dividend Yield | 10th Percentile | 1.5% |
| Poland Bottom 25% Dividend Yield | 25th Percentile | 2.8% |
| Poland Top 25% Dividend Yield | 75th Percentile | 7.9% |
Industry and Market average data is calculated daily.
Note all dividend per share amounts are annualized and not quarterly or other period.
| Date (Data in PLN) | Dividend per Share (annual) | Avg. No. Analysts |
|---|---|---|
| 2020-12-31 | ||
| 2019-12-31 |
Learn more about our ratios and growth rates in Simply Wall St’s analysis model >
- Unable to perform a dividend volatility check as Mabion has not reported any payouts.
- Unable to verify if Mabion's dividend has been increasing as the company has not reported any payouts.
Income/ dividend checks
We assess Mabion's dividend by checking for:- Firstly is the company paying a notable dividend (greater than 1.5%) - if not then the rest of the checks are ignored.
- Is current dividend yield above the bottom 25% of dividend payers? (1 check)
- Is current dividend yield above the top 25% of dividend payers? (1 check)
- Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
- If they have paid a dividend for 10 years has it increased in this time? (1 check)
- How sustainable is the dividend, can Mabion afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks) Mabion has a total score of 0/6, see the detailed checks below.
Full details on the Dividends part of the Simply Wall St company analysis model.
MAB Management
CEO
| COMPENSATION | PLN0 |
CEO Bio
Mr. Artur Chabowski served as Chairman-Supervisory Board at IFM Global Funds S.A. ( formerly known as Investment Fund Managers S.A.). Mr. Artur Chabowski served as the President of the Management Board at ACADIA since 2008. Mr. Chabowski serves as President of the Management Board at Mabion SA. Mr. Chabowski is a graduate of the Faculty of Organisation and Management at the Warsaw University of Technology. Mr. Chabowski completed post-graduate studies at the University of Princeton in the Woodrow Wilson School of Public & International Affairs.
CEO Compensation
- Artur's compensation has been consistent with company performance over the past year, both up more than 20%.
- Artur's remuneration is higher than average for companies of similar size in Poland.
Management Team
Artur Chabowski
President of the Management Board
Jaroslaw Walczak
Member of the Management Board
Slawomir Jaros
Director of Research & Development Department and Member of the Management Board
Grzegorz Grabowicz
Member of Management Board
45
Board of Directors
Robert Aleksandrowicz
Chairman of the Supervisory Board
Maciej Wieczorek
Deputy Chairman of the Supervisory Board
Bogdan Manowski
Vice Chairman of the Supervisory Board
Tadeusz Pietrucha
Independent Member of the Supervisory Board
Grzegorz Stefanski
Member of the Supervisory Board
Jacek Nowak
Member of Supervisory Board
Tomasz Jasny
Independent Member of the Supervisory Board
3.9 yrs
Artur Olech
Member of Supervisory Board
David James
Member of Supervisory Board
Robert Konski
Member of Supervisory Board
Who owns this company?
Recent Insider Transactions
| Announced | Type | Name | Entity | Role | Start | End | Shares | Max Price (PLN) | Value (PLN) | |
|---|---|---|---|---|---|---|---|---|---|---|
Management checks
We assess Mabion's management by checking for:- Is the CEO's compensation unreasonable compared to market cap? (1 check)
- Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
- Is the average tenure of the management team less than 2 years? (1 check)
- Is the average tenure of the board of directors team less than 3 years? (1 check) Mabion has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.
Note: We use the top 6 management executives and board members in our calculations.
Note 2: Insider trading include any internal stakeholders and these transactions .
Full details on the Management part of the Simply Wall St company analysis model.
MAB News
Simply Wall St News
Do Institutions Own Mabion S.A. (WSE:MAB) Shares?
Insiders often own a large chunk of younger, smaller, companies while huge companies tend to have institutions as shareholders. … So it's nice to see some insider ownership, because it may suggest that management is owner-oriented. … With a market capitalization of zł1.1b, Mabion is a small cap stock, so it might not be well known by many institutional investors.
Simply Wall St - – Full articleDo Institutions Own Shares In Mabion SA (WSE:MAB)?
The big shareholder groups in Mabion SA (WSE:MAB) have power over the company. … With a market capitalization of zł1.4b, Mabion is a small cap stock, so it might not be well known by many institutional investors. … Taking a look at the our data on the ownership groups (below), it's seems that.
Simply Wall St - – Full articleAn Intrinsic Calculation For Mabion SA (WSE:MAB) Shows It's 42.17% Undervalued
by taking the expected future cash flows and discounting them to their present value. … discounted cash flows (DCF). … If you want to learn more about discounted cash flow, the basis for my calcs can be read in detail in the Simply Wall St analysis model
Simply Wall St - – Full articleCan Mabion SA. (WSE:MAB) Improve Your Portfolio Returns?
View our latest analysis for Mabion An interpretation of MAB's beta Mabion's beta of 0.22 indicates that the stock value will be less variable compared to the whole stock market. … MAB’s beta indicates it is a stock that investors may find valuable if they want to reduce the overall market risk exposure of their stock portfolio. … As a result, this aspect of MAB indicates a higher beta than a similar size company with a lower portion of fixed assets on their balance sheet.
Simply Wall St - – Full articleWant To Invest In Mabion SA. (WSE:MAB)? Here's How It Performed Lately
After reading Mabion SA.'s (WSE:MAB) latest earnings update (30 September 2017), I found it beneficial to look back at how the company has performed in the past and compare this against the most recent numbers. … View our latest analysis for Mabion Were MAB's earnings stronger than its past performances and the industry? … Each year, for the past five years Mabion has seen an annual decline in revenue of -16.23%, on average.
Simply Wall St - – Full articleInvestors Are Undervaluing Mabion SA. (WSE:MAB) By 40%
5-year cash flow forecast 2018 2019 2020 2021 2022 Levered FCF (PLN, Millions) PLN115.15 PLN92.45 PLN129.20 PLN222.65 PLN161.15 Source Analyst x2 Analyst x2 Analyst x2 Analyst x2 Analyst x2 Present Value Discounted @ 8.35% PLN106.28 PLN78.75 PLN101.58 PLN161.56 PLN107.93 Present Value of 5-year Cash Flow (PVCF)= PLN556 The second stage is also known as Terminal Value, this is the business's cash flow after the first stage. … Terminal Value (TV) = FCF2022 × (1 + g) ÷ (r – g) = PLN161 × (1 + 1.7%) ÷ (8.3% – 1.7%) = PLN2,481 Present Value of Terminal Value (PVTV) = TV / (1 + r)5 = PLN2,481 / ( 1 + 8.3%)5 = PLN1,662 The total value is the sum of cash flows for the next five years and the discounted terminal value, which results in the Total Equity Value, which in this case is PLN2,218. … WSE:MAB Intrinsic Value Mar 15th 18 Important assumptions Now the most important inputs to a discounted cash flow are the discount rate, and of course, the actual cash flows.
Simply Wall St - – Full articleMAB Company Info
Description
Mabion S.A., a biotechnology company, researches and develops biotechnology and biosimilar drugs to treat cancer, autoimmune, and metabolic diseases in Poland. It develops MabionCD20, an oncology drug for the treatment of lymphomas and leukemia blood cancers, as well as rheumatoid arthritis; MabionHER2, an oncology drug for the treatment of breast cancer; and MabionVEGF_Fab, a drug for the treatment of various diseases resulting in vision impairment in adults. The company also develops MabionEGFR, an oncology drug for the treatment of metastatic colorectal cancer; and MabionVEGF, an oncology drug for the treatment of colon or rectal cancer, metastatic breast cancer, and metastatic or recurrent lung cancer with other anticancer drugs. Mabion S.A. was founded in 2007 and is based in Konstantynów Lódzki, Poland.
Details
| Name: | Mabion S.A. |
| MAB | |
| Exchange: | WSE |
| Founded: | 2007 |
| PLN1,002,988,433 | |
| 13,720,772 | |
| Website: | http://www.mabion.eu |
| Address: |
Mabion S.A. gen. Mariana Langiewicza 60 street, Konstantynów Lódzki, 95-050, Poland |
Listings
| Exchange Symbol | Ticker Symbol | Security | Exchange | Country | Currency | Listed on | |
|---|---|---|---|---|---|---|---|
| WSE | MAB | Common Bearer Shares | Warsaw Stock Exchange | PL | PLN | 10. Aug 2010 | |
| LSE | 0QGW | Common Bearer Shares | London Stock Exchange | GB | PLN | 10. Aug 2010 |
Number of employees
Current staff
Industry
| Biotechnology | |
| Pharmaceuticals & Biotech |
Company Analysis and Financial Data Status
| Area | Date (UTC time) |
|---|---|
| Company Analysis updated: | 2019/05/20 21:37 |
| End of day share price update: | 2019/05/20 00:00 |
| Last estimates confirmation: | 2019/05/15 |
| Last earnings filing: | 2019/04/10 |
| Last earnings reported: | 2018/12/31 |
| Last annual earnings reported: | 2018/12/31 |
All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
